Models for integrating buprenorphine therapy into the primary HIV care setting.
about
Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparitiesRetention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependenceTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.Development and evaluation of a community-based buprenorphine treatment intervention.Buprenorphine treatment in an urban community health center: what to expectManagement of HIV infection in patients with substance use problemsLinkage to care for HIV-infected heterosexual men in the United StatesTherapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centersHepatitis infection in the treatment of opioid dependence and abuse.Improving public health through access to and utilization of medication assisted treatmentValidation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS)Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program.HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implicationsPharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems.Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence."Bureaucracy & Beliefs": Assessing the Barriers to Accessing Opioid Substitution Therapy by People Who Inject Drugs in Ukraine.Finding what works: identification of implementation strategies for the integration of methadone maintenance therapy and HIV services in VietnamIntegrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.Review: the need for smoking cessation among HIV-positive smokers.The case for chronic disease management for addiction.Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxoneComparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening.Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.
P2860
Q26865313-AC14E8C2-09C7-451F-81DA-4DEAC3DB05D4Q28265279-05D31F8D-8264-4D3F-8439-8CC1123A1D3FQ30751889-39FAACF8-FA8D-48A2-A95D-05BB8AB0ADE8Q33667902-F933DCA4-90EF-48F7-9271-DCB319728BA9Q33735289-33E970AA-A4EC-4F58-81DF-DD1B66D527C4Q34113784-AFD70BD2-03CA-4345-8D55-2DFDE88DBAE2Q35019900-09B42B08-AE7C-4803-93E8-2513068AB97BQ35061983-A670FE5A-0D29-44DC-A455-7D378D09A90AQ35112836-683F24A1-9890-48A5-8F0B-9B362FC86603Q35389163-0261C8F1-00E6-4EF5-9336-28D8580EA4C3Q35534893-F1B64730-0A46-4916-B99D-255F1059E66CQ35618756-4DEF6A1E-F963-4A92-BD16-B93A385393DFQ35623599-74C00A9B-A66A-4D98-9385-E691780594B8Q35686969-14F52CFD-4E85-4A3E-A01A-EDE4CACDC2AFQ35726267-2E66974D-1F36-4CEF-9369-051D8C6A4C95Q36156096-AAA736D4-00E0-46D7-B376-A60F5D962113Q36248583-508BCF64-AB78-4273-98AF-74697926F283Q36468227-3857F285-1899-4E95-8F09-429D4588DC97Q36508384-F3CFBCEE-D28D-43E2-B6E7-F3BC7D14C57BQ36798287-5B9C21B1-F5F7-44D2-AFA4-B745CB2FD385Q36815377-C9C60BB0-587B-4893-8624-6C4C156DA4B7Q36906548-F3EB1A6B-CE8C-451D-B7E8-330D13B04510Q37227121-F945429A-A563-4D28-9CDE-8EFAF29AC81EQ37247180-E136D204-1862-4866-9B4A-C68B9E7B1A74Q37374221-4004BC3E-2D27-4BE8-9E5F-F83BBF24AF96Q37397043-0F0A2C81-86B8-4E2B-B73C-25BE63AA9E05Q37425629-D2AAF31E-63F3-4359-A6CD-B5A129F7E43CQ43218767-C9E1BF80-3290-4750-BA36-1F9EB4C687F2Q44500239-9D508F49-5820-44D6-81AE-49319564BF0BQ50915503-416BE396-E366-4E80-AA3A-B17D778F8E8AQ52306466-79864DFE-42B4-47EE-9121-71865782D73B
P2860
Models for integrating buprenorphine therapy into the primary HIV care setting.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Models for integrating buprenorphine therapy into the primary HIV care setting.
@en
Models for integrating buprenorphine therapy into the primary HIV care setting.
@nl
type
label
Models for integrating buprenorphine therapy into the primary HIV care setting.
@en
Models for integrating buprenorphine therapy into the primary HIV care setting.
@nl
prefLabel
Models for integrating buprenorphine therapy into the primary HIV care setting.
@en
Models for integrating buprenorphine therapy into the primary HIV care setting.
@nl
P2093
P356
P1476
Models for integrating buprenorphine therapy into the primary HIV care setting.
@en
P2093
Duncan Smith-Rohrberg
Frederick L Altice
R Douglas Bruce
P304
P356
10.1086/500200
P407
P50
P577
2006-01-24T00:00:00Z